Parvovirus B19 infection in pregnancy

被引:77
作者
de Jong, EP
de Haan, TR
Kroes, ACM
Beersmab, MFC
Oepkes, D
Walther, FJ
机构
[1] Leiden Univ, Med Ctr, Dept Pediat, Div Neonatol, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Med Microbiol, Clin Microbiol Lab, Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Obstet, Leiden, Netherlands
关键词
parvovirus B19; intrauterine infection; fetal anemia; intrauterine transfusion;
D O I
10.1016/j.jcv.2006.01.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Parvovirus B19 is a small single-stranded DNA virus and a potent inhibitor of erythropoiesis, Clue to its cytotoxicity to erythroid progenitor cells. Infection with parvovirus B19 during pregnancy can cause several serious complications in the fetus, such as fetal anemia, neurological anomalies, hydrops fetalis, and fetal death. Early diagnosis and treatment of intrauterine parvovirus B19 infection is essential in preventing these fetal complications. Testing maternal serum for IgM antibodies against parvovirus B19 and DNA detection by PCR can confirm maternal infection. If maternal infection has occurred, ultrasound investigation of the fetus and measurement of the peak systolic flow velocity of the middle cerebral artery are sensitive non-invasive procedures to diagnose fetal anemia and hydrops. Intrauterine transfusion is Currently the only effective treatment to alleviate fetal anemia, but if the fetus is (near) term, induction of delivery should be considered. Most maternal infections with parvovirus B19 occur through contact with infected children at home. Individual counseling Of Susceptible pregnant women will reduce unnecessary fetal deaths. (C) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 45 条
  • [1] EXPERIMENTAL PARVOVIRAL INFECTION IN HUMANS
    ANDERSON, MJ
    HIGGINS, PG
    DAVIS, LR
    WILLMAN, JS
    JONES, SE
    KIDD, IM
    PATTISON, JR
    TYRRELL, DAJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1985, 152 (02) : 257 - 265
  • [2] Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1
    Ballou, WR
    Reed, JL
    Noble, W
    Young, NS
    Koenig, S
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (04) : 675 - 678
  • [3] Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples
    Beersma, MFC
    Claas, ECJ
    Sopaheluakan, T
    Kroes, ACM
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2005, 34 (01) : 71 - 75
  • [4] BOND PR, 1986, LANCET, V1, P448
  • [5] Bosman A, 2002, INFECT B, V13, P215
  • [6] BROWN T, 1984, LANCET, V2, P1033
  • [7] OCCUPATIONAL RISK-FACTORS FOR INFECTION WITH PARVOVIRUS B19 AMONG PREGNANT-WOMEN
    CARTTER, ML
    FARLEY, TA
    ROSENGREN, S
    QUINN, DL
    GILLESPIE, SM
    GARY, GW
    HADLER, JL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (02) : 282 - 285
  • [8] Parvovirus B19 and the pathogenesis of anaemia
    Chisaka, H
    Morita, E
    Yaegashi, N
    Sugamura, K
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2003, 13 (06) : 347 - 359
  • [9] Cohen BJ, 2005, FETAL MATERN MED REV, V16, P23
  • [10] Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection
    Cosmi, E
    Mari, G
    Delle Chiaie, L
    Detti, L
    Akiyama, M
    Murphy, J
    Stefos, T
    Ferguson, JE
    Hunter, D
    Hsu, CD
    Abuhamad, A
    Bahado-Singh, R
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (05) : 1290 - 1293